Company Filing History:
Years Active: 2015
Title: Angeliqueo E Padilla: Innovator in Ocular and Nasal Treatments
Introduction
Angeliqueo E Padilla is a notable inventor based in the United States. He has made significant contributions to the field of pharmaceuticals, particularly in the development of aqueous liquid compositions for treating ocular and nasal inflammation. Despite having no patents to his name, his work has been influential in the medical community.
Latest Patents
Padilla's latest patents include two innovative aqueous liquid compositions. The first patent, titled "Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)phenylacetic Acid," describes a formulation that includes 2-amino-3-(4-bromobenzoyl)phenylacetic acid, a non-ionic surfactant, and a preservative. This composition is designed to maintain at least 90 percent of the active ingredient after storage at 60 °C for four weeks. It is particularly useful for treating ocular or nasal inflammation of diverse etiology. The second patent, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl)phenylacetic Acid," focuses on a stable liquid preparation that can be used as eye drops or nasal drops. This preparation is effective for treating conditions such as blepharitis, conjunctivitis, scleritis, and allergic rhinitis.
Career Highlights
Throughout his career, Padilla has worked with prominent companies in the pharmaceutical industry, including Bausch & Lomb Pharma Holdings Corp. and Bausch & Lomb Incorporated. His experience in these organizations has allowed him to develop and refine his innovative formulations.
Collaborations
Padilla has collaborated with notable professionals in his field, including Shirou Sawa and Shuhei Fujita. These partnerships have contributed to the advancement of his research and the successful development of his patented compositions.
Conclusion
Angeliqueo E Padilla is a dedicated inventor whose work in aqueous liquid compositions has the potential to significantly impact the treatment of ocular and nasal conditions. His innovative approaches and collaborations highlight his commitment to advancing pharmaceutical science.